Table 1:
Clinical and demographic characteristics of all patients with initially unresectable colorectal liver metastases (CRLM) who underwent hepatic arterial infusion (HAI) and systemic chemotherapy, stratified by cohorts that converted to resection versus those remaining unresectable (CEA: carcinoembryonic antigen)
| All patients | Converted to Resection |
Persistently unresectable |
p-value | ||
|---|---|---|---|---|---|
| Number of patients | 128 | 51 | 77 | ||
| Gender | Male | 82 (64.1%) | 30 (58.8%) | 52 (67.5%) | 0.35 |
| Female | 46 (35.9%) | 21 (41.2%) | 25 (32.5%) | ||
| Age at Primary Diagnosis, years | Median (range) | 51.5 (25.3–75.3) | 51.7 (28.9–70.7) | 50.9 (25.3–75.3) | 0.94 |
| Age at CRLM Diagnosis, years | Median (range) | 51.7 (25.4–75.3) | 52.3 (29.4–70.9) | 51.2 (25.4–75.3) | 0.84 |
| Location of Primary Tumor | Left Colon | 35 (27.3%) | 10 (19.6%) | 25 (32.5%) | 0.08 |
| Left Colon | 47 (36.7%) | 24 (47.1%) | 23 (29.9%) | ||
| Rectum | 45 (35.2%) | 16 (31.4%) | 29 (37.7%) | ||
| Colon, NOS | 1 (0.8%) | 1 (2%) | 0 (0%) | ||
| Primary Tumor Size, mm | Median (range) | 41 (0–130) | 40 (12–130) | 43 (0–112) | 0.88 |
| N Missing | (9) | (1) | (8) | ||
| Primary Pathologic T-classification | T0-T3 | 89 (69.5%) | 43 (84.3%) | 46 (59.7%) | 0.24 |
| T4a-T4b | 3 (2.3%) | 3 (5.9%) | 0 (0%) | ||
| Unknown | 36 (28.1%) | 5 (9.8%) | 31 (40.3%) | ||
| Primary Pathologic Nodal Status | Negative | 24 (18.8%) | 1 14 (27.5%) | 10 (13%) | 0.040 |
| Positive | 103 (80.5%) 1 | 36 (70.6%) | 67 (87%) | ||
| Unknown | 1 (0.8%) | 1 (2%) | 0 (0%) | ||
| Disease Free Interval, months* | Median (range) | 0.5 (0.0 – 25.1) 1 | 0.7 (0.0 – 11.1) | 0.4 (0.0 – 25.1) | 0.002 |
| Pre-HACEA (ng/mL) | Median (range) | 62.9 (0.5–15969) | J 59.0 (0.5–7337) | 64.6 (0.9–15969) | >0.95 |
| N Missing | (2) | (0) | (2) | ||
| Largest CRLM Size, mm | Median (range) | 42 (11–210) | 51 (13–210) | 36 (11–125) | 0.032 |
| Number of CRLM | ≤4 | . 8 (6.3%) | 3 (5.9%) | 5 (6.5%) | >0.95 |
| >4 | 120 (93.8%) | 48 (94.1%) | 72 (93.5%) | ||
| Clinical Risk Score (CRS) | Low Risk (0–2) | 10 (7.8%) | 5 (9.8%) | 5 (6.5%) | 0.52 |
| High Risk (3–5) | 115 (89.8%) | 1 45 (88.2%) 1 | 70 (90.9%) | ||
| Unknown | 3 (2.3%) | 1 (2%) | 2 (2.6%) | ||
| Pre-HAChemotherapy | Yes | 100 (78.1%) | 33 (64.7%) | 67 (87%) | 0.004 |
| No | 28 (21.9%) | 18 (35.3%) | 10 (13%) | ||
| Pre-HAExtrahepatic Disease | Yes | 49 (38.3%) | 1 16 (31.4%) | 33 (42.9%) | 0.20 |
| No | 79 (61.7%) | 35 (68.6%) | 44 (57.1%) | ||
| HAI-related Grade 3–4 Complications | Yes | 11 (8.6%) | 4 (7.8%) | 7 (9.1%) | >0.95 |
| No | 117 (91.4%) | 47 (92.2%) | 70 (90.9%) | ||
| CEA 6 months post-HAI | Median (range) | 6.0 (0.9–1506) | . 3.6 (0.9–1189) 1 | 11.4 (1.6–1506) | <0.001 |
*
DFI calculated between diagnosis of primary and development of liver metastasis; “0 “ is synchronously detected